Dr. Reddy’s and RDIF enter an agreement for 100 million doses of Sputnik V COVID19 vaccine

October 5, 20200

As the COVID-19 vaccine candidate, Sputnik V emerged out of Russia and ventured globally; it was met with skepticism due to lack of publicly available data and the short span of trials lasting only 42 days, reinstating existing doubts. This view changed with their publication of clinical Phase I and Phase II trial results in The Lancet, enabling scientists across the world to compare, benchmark and position the vaccine amidst others. The Russian Direct Investment Fund (RDIF), the Gamaleya National Research Institute of Epidemiology and Microbiology and Sistema PJSFC were jointly responsible for the production of vaccine along with a joint venture between RDIF and R-pharm, scaling up the manufacturing process.

As the vaccine commercialization process will soon be underway post Phase III completion, RDIF is seeking partnerships with large national Pharmaceutical companies in various nations to manufacture and distribute the vaccine intra-nationally and has formed alliances in Kazakhstan, Mexico, India, Uzbekistan, India and Nepal.

The partnership forged by RDIF and Dr. Reddy’s is the largest among their other partnerships with a commitment to supply 100 million doses after achieving regulatory approval in India. Dr. Reddy’s will conduct clinical trials for this human adenoviral vector platform-based vaccine in about 1000 to 2000 participants in various private and Government Hospitals to gauge vaccine’s safety and efficacy for the Indian population as well as meet the standards set by Indian regulators.

India witnessed large partnerships for manufacturing the COVID-19 vaccine which is a testament to global faith in production capabilities in the country. These partnerships were set in motion by AstraZeneca collaborating with Serum Institute of India (SII) to manufacture 1 billion doses in June. This was followed by SII entering a new collaboration with GAVI, the Bill & Melinda Gates Foundation and The Vaccine Alliance, to manufacture 100 million doses of Novavax and AstraZeneca vaccine candidates for low- and middle-income countries (LMICs) under COVAX Advance Market Commitment (AMC). While additional vaccine products from Bharat Biotech International, Zydus Cadila, Biological E, Panacea Biotec, Indian Immunologicals, Mynvax and SII in the country may lead to competition to the Sputnik V, this deal is vital considering the exponential spread of the pandemic and the number of doses required for immunizing the large population.t

Leave a Reply

Your email address will not be published. Required fields are marked *